Epidemiologic and molecular prognostic review of glioblastoma.
Epidemiologic and molecular prognostic review of glioblastoma.
复制标题
DOI：
10.1158/1055-9965.epi-14-0275
复制
发表时间：
2014-10
期刊：
影响因子：
--
通讯作者：
Villano JL
中科院分区：
文献类型：
--
作者：
Thakkar JP;Dolecek TA;Horbinski C;Ostrom QT;Lightner DD;Barnholtz-Sloan JS;Villano JL
胶质母细胞瘤 (GBM) 是最常见、最具侵袭性的原发性中枢神经系统恶性肿瘤，中位生存期为 15 个月。 GBM 的平均发病率为 3.19/10 万人口，中位诊断年龄为 64 岁。男性以及白人和非西班牙裔的发病率较高。已经对 GBM 的许多遗传和环境因素进行了研究，但大多数都是散发性的，并且尚未确定占 GBM 很大比例的危险因素。然而，已经确定了一些有利的临床预后因素，包括诊断时年龄较小、小脑位置、高性能状态和最大程度的肿瘤切除。 GBM 由原发性和继发性亚型组成，它们通过不同的遗传途径进化，影响不同年龄的患者并具有不同的结果。我们利用美国中央脑肿瘤登记处 (CBTRUS) 2006-2010 年的新数据报告了 GBM 当前的流行病学，并展示和讨论了发病率和生存率的趋势。我们还对 GBM 中的分子标志物进行了简要回顾，这些分子标志物有助于区分生物学上相似的 GBM 亚型，并具有预后和预测价值。
Glioblastoma (GBM) is the most common and aggressive primary CNS malignancy with a median survival of 15 months. The average incidence rate (IR) of GBM is 3.19/100,000 population and the median age of diagnosis is 64 years. Incidence is higher in men and individuals of white race and non-Hispanic ethnicity. Many genetic and environmental factors have been studied in GBM but the majority are sporadic and no risk factor accounting for a large proportion of GBMs has been identified. However, several favorable clinical prognostic factors are identified including, younger age at diagnosis, cerebellar location, high performance status and maximal tumor resection. GBMs comprise of primary and secondary subtypes which evolve through different genetic pathways, affect patients at different ages and have differences in outcomes. We report the current epidemiology of GBM with new data from the Central Brain Tumor Registry of the United States (CBTRUS) 2006–2010 as well as demonstrate and discuss trends in incidence and survival. We also provide a concise review on molecular markers in GBM that have helped distinguish biologically similar subtypes of GBM and have prognostic and predictive value.